Atea Pharmaceuticals Inc Ordinary Shares AVIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.91
- Day Range
- $4.75–5.00
- 52-Week Range
- $2.78–6.45
- Bid/Ask
- $4.66 / $5.10
- Shares Outstanding
- 80.03M
- Market Cap
- $399.34M
- Volume/Avg
- 306,553 / 331,026
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 6.38%
Company Profile
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 55
- Website
- https://www.ateapharma.com
Valuation
|
Metric
|
AVIR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.67 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AVIR
Financial Strength
|
Metric
|
AVIR
|
|---|---|
Quick Ratio | 7.67 |
Current Ratio | 7.89 |
Interest Coverage | — |
Quick Ratio
AVIR
Profitability
|
Metric
|
AVIR
|
|---|---|
Return on Assets (Normalized) | −43.44% |
Return on Equity (Normalized) | −47.69% |
Return on Invested Capital (Normalized) | −51.74% |
Return on Assets
AVIR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Sf&$xZ | LOCK|>#!MV | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?T#!F? | LOCK|!>s^ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|%>Zd@kk | LOCK|t>< | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&#$?YRp | LOCK|B^%& | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Y<H?Zp | LOCK|Wh | $36B | |||
| Moderna Inc
MRNA
| LOCK|bstC?D | LOCK|#vJ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|HVg#xvD | LOCK|vWlD | $25B | |||
| Incyte Corp
INCY
| LOCK|^!j#?XC | LOCK|Nr | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?Pj$jc$ | LOCK|>? | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|SmW!dX | LOCK|Vz | $17B |
United States